Edaravone, a new therapeutic option in amyotrophic lateral sclerosis: Evaluation of challenges in the drug accessibility
Łukasz Puchała 1  
,   Stanisław Maksymowicz 2  
,   Tomasz Siwek 3  
,   Marcin P. Mycko 3  
More details
Hide details
Department of Pharmacology and Toxicology, Faculty of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Poland
Department of Psychology and Sociology of Health and Public Health, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Poland
Department of Neurology, Faculty of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Poland
Łukasz Puchała   

Department of Pharmacology and Toxicology, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Warszawska 30, 10-028 Olsztyn, Poland. Tel.: +48 508 550 544
Submission date: 2019-11-21
Final revision date: 2020-07-20
Acceptance date: 2020-07-20
Online publication date: 2020-08-06
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease, with about 3–4 years median survival from the onset of symptoms. Only two therapies for ALS have been proven effective in slowing down this condition, riluzole and edaravone. Recently approved edaravone, either original or generic, is not registered in Poland. It can only be used after special approval of Polish Ministry of Health. The costs of payment have to be covered by patient in full.

In this article we will describe the public demand of edaravone in Poland for ALS treatment and problems related to prescribing the drug, like procedures and prices.

Material and methods:
This article is based on the available literature and on data obtained from Polish Ministry of Health.

Results and discussion:
The high cost of therapy affects the relatively widespread use of generic medicines not registered in Europe. We identify mechanisms of the demand and supply for various formulations of edaravone in Poland. These information should be of relevance to many other countries, especially within the European Union.

Medicines available from licensed manufacturer are more expensive than offers available on-line. Although original chain of distribution presents with unrivaled warranty to avoid purchasing of adulterated drug we report the challenges of the edaravone treatment initiation in ALS patients in Poland.

None declared.
None declared.
Chiò A, Logroscino G, Traynor BJ, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41(2):118–130.
Arthur KC, Calvo A, Price TR, Geiger JT, Chiò A, Traynor BJ. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat Commun. 2016;7:1–6.
European Medicines Agency. EU/3/14/1399. Published: February 26, 2015. Accessed: July 15, 2019.
Rada Przejrzystości. [Position of the Transparency Council on the legitimacy of granting the reimbursement consent for Radicut (edaravonum) in the indication: amyotrophic lateral sclerosis]. Published: November 27, 2017. Accessed: July 15, 2019.
Bäumer D, Talbot K, Turner MR. Advances in motor neurone disease. J R Soc Med. 2014;107(1):14–21.
Turner MR, Hardiman O, Benatar M, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 2013;12(3):310–322.
Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol. 2011;7(11):603–615.
Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1218–1226. Erratum in: Neurology. 2010;74(9):781; Neurology. 2009;73(24):2134.
Radicava (edaravone injecton). For intravenous use. Accessed: July 15, 2019.
Puchała Ł, Maksymowicz S. [Directions of searching for new drugs for ALS]. Farm Pol. 2019;75(5):247–250. [in Polish].
Barczewska M, Grudniak M, Maksymowicz S, et al. Safety of intrathecal injection of Wharton’s jelly-derived mesenchymal stem cells in amyotrophic lateral sclerosis therapy. Neural Regen Res. 2019;14(2):313–318.
Siwek T, Maksymowicz W, Barczewska M, et al. Mesenchymal stem cell (MSC) transplantation in patients with amyotrophic lateral sclerosis (ALS): Is there a “responder population”? J Neurol Neurosci. 2018;9(3):1–6.
Gugliandolo A, Bramanti P, Mazzon E. Mesenchymal stem cells: A potential therapeutic approach for amyotrophic lateral sclerosis? Stem Cells Int. 2019:1–16.
Kuzma-Kozakiewicz M, Kwieciński H. New therapeutic targets for amyotrophic lateral sclerosis. Expert Opin Ther Targets. 2011;15(2):127–143.
Scott A. On the treatment trail for ALS. Nature. 2017;550(7676):S120-S121.
Ng L, Khan F, Young CA, Galea M. Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2017;1:CD011776.
Bello-Haas VD. Physical therapy for individuals with amyotrophic lateral sclerosis: current insights. Degener Neurol Neuromuscul Dis. 2018;8:45–54.
Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347(9013):1425–1431.
Bensimon G, Lacomblez L, Meininger V; ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330(9):585–591.
Center for Drug Evaluation and Research. Approval Package for Radicava Injection, 30 mg / 100mL. Published: May 5, 2017. Accessed: 15.07.2019.
Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505–512.
Oskarsson B, Gendron TF, Staff NP. Amyotrophic lateral sclerosis: An update for 2018. Mayo Clinic Proc. 2018;93(11):1617–1628.
Edaravone (MCI-186) ALS 16 Study Group. A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(Sup1):11–19.
Luo L, Song Z, Li X, et al. Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis-a systematic review and meta-analysis. Neurol Sci. 2019;40(2):235–241.
Palumbo JM, Hubble J, Apple S, et al. Post-hoc analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(5–6):421–431.
Abraham A, Nefussy B, Fainmesser Y, Ebrahimi Y, Karni A, Drory VE. Early post-marketing experience with edaravone in an unselected group of patients with ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(3–4):260–263.
Yaiswal MK. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med Res Rev. 2019;39(2):733–748.
Yoshino H. Edaravone for the treatment of amyotrophic lateral sclerosis. Expert Rev Neurother. 2019;19(3):185–193.
Arcila-Londono X, Walk D, Vota S, et al. General characteristics of edaravone use in the natural history of ALS and other motor neuron disorders consortium dataset (NeuroBANK™). Neurology. 2019;92(Suppl 15).
TheSocialMedwork. Radicut/Radicava (edaravone). Accessed: July 15, 2019.
31. Edastar Injection 20 mL. Accessed: July 15, 2019.
Underwood G. Mitsubishi Tanabe pulls ALS drug from EMA assessment. Published: May 31, 2019. Accessed: July 15, 2019.